Kymera Therapeutics (KYMR) News Today $25.46 +0.03 (+0.12%) Closing price 04:00 PM EasternExtended Trading$25.48 +0.02 (+0.08%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Fmr LLCFmr LLC trimmed its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,830,423 shares of the company's stock after selling 278,71April 15 at 4:49 AM | marketbeat.com14,126 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by ExodusPoint Capital Management LPExodusPoint Capital Management LP acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 14,126 shares of the company's stock, valued at appApril 14 at 4:11 AM | marketbeat.comNorges Bank Buys New Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Norges Bank purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 91,231 shares of the company's stock, valuedApril 13 at 4:03 AM | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Shares Down 6.9% - What's Next?Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.9% - What's Next?April 11, 2025 | marketbeat.comKymera Therapeutics appoints Goodman as Chief Business OfficerApril 9, 2025 | msn.comKymera Therapeutics Appoints Noah Goodman as Chief Business OfficerApril 9, 2025 | globenewswire.comKymera Therapeutics Appoints Noah Goodman as Chief Business OfficerApril 9, 2025 | globenewswire.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by BrokeragesKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating anApril 9, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Sets New 52-Week Low - Here's WhyKymera Therapeutics (NASDAQ:KYMR) Hits New 1-Year Low - Here's WhyApril 9, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Atika Capital Management LLCAtika Capital Management LLC increased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 40.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 136,500 shares of the comApril 8, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Sells 33,887 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Massachusetts Financial Services Co. MA cut its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 7.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 419,490 shares of the company's stock after selling 33,April 8, 2025 | marketbeat.comVanguard Group Inc. Raises Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Vanguard Group Inc. boosted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,887,312 shares of the company's stock after purchasiApril 8, 2025 | marketbeat.comKymera Therapeutics IncApril 6, 2025 | uk.investing.comCinctive Capital Management LP Sells 20,766 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Cinctive Capital Management LP lowered its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 36.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,035 shares of the company's stock after sellinApril 6, 2025 | marketbeat.comSchroder Investment Management Group Acquires 20,204 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Schroder Investment Management Group boosted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 163,896 shares of the comApril 6, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Purchased by Wellington Management Group LLPWellington Management Group LLP grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 14.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,307,326 shareApril 4, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Down 6.1% - Should You Sell?Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.1% - Time to Sell?April 3, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Prudential Financial Inc.Prudential Financial Inc. trimmed its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 20.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,817 shares of the company's stock after sApril 3, 2025 | marketbeat.comKymera Therapeutics is Now Oversold (KYMR)April 2, 2025 | nasdaq.comKymera Therapeutics (NASDAQ:KYMR) Reaches New 12-Month Low - Time to Sell?Kymera Therapeutics (NASDAQ:KYMR) Reaches New 12-Month Low - Here's WhyApril 1, 2025 | marketbeat.comSwiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Swiss National Bank raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 15.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 76,200 shares of the company's stock after purchasing an additioMarch 27, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Trading Down 6.2% - Should You Sell?Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.2% - Here's WhyMarch 26, 2025 | marketbeat.comSquarepoint Ops LLC Sells 25,151 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Squarepoint Ops LLC decreased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 34.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 48,374 shares of the company's stock after selling 25,151 shares duringMarch 26, 2025 | marketbeat.comVictory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Victory Capital Management Inc. grew its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 174.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,899 shares of the company's stock after buying an additionMarch 21, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Charles Schwab Investment Management Inc. lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 387,1March 21, 2025 | marketbeat.comCitigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy RecommendationMarch 14, 2025 | msn.comCitigroup Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR)Citigroup assumed coverage on shares of Kymera Therapeutics in a research note on Thursday. They issued a "buy" rating and a $52.00 target price for the company.March 14, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fifteen ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, eleven hMarch 14, 2025 | marketbeat.comKymera Therapeutics initiated with a Buy at CitiMarch 13, 2025 | markets.businessinsider.comE Fund Management Co. Ltd. Grows Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)E Fund Management Co. Ltd. raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 23.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,068 shares of the company's stock after buMarch 8, 2025 | marketbeat.comFY2025 Earnings Forecast for KYMR Issued By B. RileyKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Equities researchers at B. Riley issued their FY2025 earnings per share estimates for Kymera Therapeutics in a research note issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($3.95) perMarch 6, 2025 | marketbeat.comTime To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) OutlookMarch 6, 2025 | finance.yahoo.comKymera Therapeutics announces new performance-based stock planMarch 5, 2025 | uk.investing.comJeremy G. Chadwick Sells 1,383 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) StockKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy G. Chadwick sold 1,383 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.March 4, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $68,238.45 in StockKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Ellen Chiniara sold 2,241 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares of the company's stock, valued at $2,438,588.25. This represents a 2.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.March 4, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce N. Jacobs Sells 7,035 SharesKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 4, 2025 | marketbeat.comStifel Nicolaus Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)March 4, 2025 | markets.businessinsider.comQ1 Earnings Forecast for KYMR Issued By B. RileyKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of Kymera Therapeutics in a report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings per share ofMarch 4, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy G. Chadwick Sells 1,383 SharesMarch 4, 2025 | insidertrades.comQ3 Earnings Forecast for KYMR Issued By HC WainwrightKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Kymera Therapeutics in a report issued on Friday, February 28th. HC Wainwright analyst A. Fein forecasts that the company will post earnings pMarch 3, 2025 | marketbeat.comAnalysts Set Expectations for KYMR Q2 EarningsKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at Brookline Capital Management issued their Q2 2025 earnings estimates for shares of Kymera Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Brookline Capital Management analyst L. CannMarch 3, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their EstimatesMarch 1, 2025 | finance.yahoo.comKymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC WainwrightHC Wainwright raised their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research note on Friday.March 1, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Announces Earnings ResultsKymera Therapeutics (NASDAQ:KYMR - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%.February 28, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Down 13.9% on Disappointing EarningsKymera Therapeutics (NASDAQ:KYMR) Shares Down 13.9% on Disappointing EarningsFebruary 28, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Dyne Therapeutics (DYN) and Kymera Therapeutics (KYMR)February 28, 2025 | markets.businessinsider.comHow Long Is Kymera Therapeutics' Cash Runway?February 28, 2025 | finance.yahoo.comKymera Therapeutics price target lowered to $54 from $60 at H.C. WainwrightFebruary 28, 2025 | markets.businessinsider.comKymera Therapeutics (KYMR) Receives a Buy from Piper SandlerFebruary 28, 2025 | markets.businessinsider.comKymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...February 28, 2025 | finance.yahoo.com Remove Ads Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼1.150.78▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼105▲KYMR Articles Average Week Remove Ads Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LEGN News Today BPMC News Today SRPT News Today TLX News Today AXSM News Today KRYS News Today NUVL News Today GRFS News Today ELAN News Today VRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYMR Stock Free KYMR Stock Alerts